The company is helping to usher in a new era of data transparency.
Big data can bring big value to research and development of medicines, so Pfizer’s Worldwide Research & Development and Strategy, Portfolio & Commercial Operations teams are working with Massachusetts General Hospital and IBM on a Metabolic Databook (MDB). The MDB uses anonymized and properly consented patient-level data from electronic medical records, genetic profiles and wearable health devices to improve the understanding of pathways and targets for drug discovery, identify people who are best suited for enrollment in our clinical trials, and identify patients who would most benefit from our approved medicines. The team has developed a model that predicts patients at risk of rapid development of Type II diabetes, and is working on a model to predict who among them is at risk of developing diabetic complications.
“Once this information is gathered, it can lead to new insights about heart and metabolic diseases that could help drive progress in our labs and deliver better outcomes for patients,” noted David Kreutter, Vice President of Pfizer’s Business Analytics and Insights team.